-
2024-512696-12-00
4
2025-06-24
BCR-ABL1+ Chronic Myeloid Leukemia
-
2024-515764-31-00
10
2025-06-13
Non-small cell lung cancer
-
2024-511534-12-00
7
2025-06-10
Advanced or Metastatic Solid Tumours
-
2023-508112-35-00
4
2025-04-15
ROS1-positive non-small cell lung cancer (NSCLC) with active brain met
-
2024-512960-75-00
5
2025-02-04
Resectable Non-small cell lung cancer
-
2024-519825-39-00
4
2025-01-30
Locally advanced colon cancer (LACC)
-
2024-511596-15-00
4
2024-12-26
Liver Diseases, Alcoholic
-
2023-509717-36-00
5
2024-12-16
AF patients who have undergone successful PCI
-
2024-512279-10-00
5
2024-11-25
Triple Negative Breast Cancer
-
2023-504620-26-00
4
2024-11-04
Triple negative breast cancer
-
2023-505871-63-00
5
2024-04-08
ER+, HER2- metastatic breast cancer following endocrine and CDK 4/6 in
-
2023-503412-33-00
5
2024-03-29
Stage IIIB-IIIC or Stage IV KRAS G12C-mutant non-small cell lung cance
-
2023-504031-41-00
5
2024-03-25
ER+/HER2- Early Breast Cancer
-
2023-503224-66-00
5
2023-10-31
Atrial Fibrillation
-
2024-516330-35-00
5
2021-09-29
Non-Small Cell Lung Cancer
-
2024-515063-66-00
4
2021-03-30
Early stage classical Hodgkin Lymphoma (cHL) without bulky lesions and
-
2022-502706-33-00
6
2018-01-10
Patients with invasive breast cancer in early stages
-
2025-521067-13-00
5
2026-04-24
Atherosclerotic Cardiovascular Disease (ASCVD)
-
2023-508827-10-00
4
2025-10-13
Patients with primary operable stage II, grade 2 or 3, Ki67 #20%, HR+/
-
2024-519000-27-00
5
2025-07-17
Hypertension
-
2023-507306-13-00
4
2025-04-13
HER2-positive unresectable locally recurrent or metastatic breast canc
-
2024-510719-31-00
5
2025-01-24
Moderate to Severe Vasomotor Symptoms (VMS)
-
2023-509947-29-00
4
2024-07-18
Anemia in patients with very low, low or intermediate risk myelodyspla
-
2023-506668-15-00
5
2024-06-17
Relapsed or Refractory Multiple Myeloma (RRMM)